Tetra Bio-Pharma has announced results from the artificial intelligence (AI) study of ARDS-003, along with Favipiravir, against acute respiratory distress syndrome (ARDS), Sepsis, and Covid-19 through the PREPAiRE platform.
HALIFAX, Nova Scotia, November 12, 2021 – Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that the Phase 3 PRESECO (PREventing SEvere COVID-19) clinical trial evaluating oral antiviral Avigan®/Reeqonus™(favipiravir) for the treatment of mild-to-moderate COVID-19 did not achieve statistical significance on the primary endpoint of time to sustained clinical recovery. Additional analyses of the trial data are ongoing. The clinical trial enrolled 1,231 patients with mild-to-moderate COVID-19 from 38 study sites across the United States, Mexico, and Brazil.
Tokyo: Fujifilm Holdings Corp has ended the development of its anti-influenza dr ..
Fujifilm Toyama Chemical Co. has announced a pause in enrollment, as of the end of March, in the currently ongoing phase III clinical trial in Japan concerning its anti-influenza drug Avigan Tablet (favipiravir), targeting patients infected with novel coronavirus infections (COVID-19).
A new drug with the active ingredient favipiravir manufactured by Hungarian pharmaceutical company Egis has been licenced for treatment of Covid-19 by the National Institute of Pharmacy and Nutrition (OGYEI), the institute said on Saturday.
We won the API Supplier of the Year Award for our strong commitment as a reliable API supplier to global formulating companies but also to take on the challenge of being part of the solution to address the pandemic. The nomination reflects on Dr. Reddy’s efforts to bring science, technology, and innovation together to provide a COVID-19 portfolio from prevention (SPUTNIK V) to cure (Remdesivir, Favipiravir, etc..).
We won the API Supplier of the Year Award for our strong commitment as a reliable API supplier to global formulating companies but also to take on the challenge of being part of the solution to address the pandemic. The nomination reflects on Dr. Reddy’s efforts to bring science, technology, and innovation together to provide a COVID-19 portfolio from prevention (SPUTNIK V) to cure (Remdesivir, Favipiravir, etc..).
COVID sufferers in the UK are now able to access a course of tablets from their GP to avoid the need for hospitalisation. AiPharma’s antiviral treatment, favipiravir, is currently taken orally over a course of 7-14 days.
Eight former FDA officials, including former FDA commissioner Andrew von Eschenbach and multiple deputy commissioners, submitted an amicus brief to the Supreme Court yesterday — asking for the Court to review the Mississippi Supreme Court decision that ruled against J&J earlier this year.
Appili Therapeutics, the biopharmaceutical company focused on drug development for infectious diseases, and AiPharma have announced a strategic alliance to advance the global development of Avigan®/Reeqonus™ (favipiravir), a broad-spectrum oral antiviral potential treatment and prevention of COVID-19.